CD47 and neoplasm: Similarly, IMM0306, a CD20 x CD47 BsAb developed by ImmuneOnco has achieved remarkable therapeutic effects in various tumor models and showed no binding to human erythrocytes in pre-clinical study (Yu et al. 2020).